All In Biotech

NDA 208255 · Mylan

Symfi Lo

Efavirenz, Lamivudine, Tenofovir Disoproxil Fumarate · Oral

Priority reviewDiscontinued

Last checked: Nov 19, 2026Latest source record: Oct 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 5, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

432

116 Phase 3, 6 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 5, 2018 Original approval · Type 3 - New Dosage Form · priority review LabelLetterReview
1 products under this application
  • SYMFI LO · EFAVIRENZ 400MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Efavirenz" as an intervention, any sponsor and status, largest first.

All 432 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Symfi Lo (Efavirenz/Lamivu/Tenofov Disop)

2024 spending

$63K

Beneficiaries

n/a

24 claims

Per beneficiary

n/a

$52.65 per unit

View as table
YearSpending
2020$462,760
2021$236,943
2022$129,278
2023$134,569
2024$63,185

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,020 on PubMed

Sponsor: Mylan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.